1. Home
  2. EDRY vs BOLD Comparison

EDRY vs BOLD Comparison

Compare EDRY & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EuroDry Ltd.

EDRY

EuroDry Ltd.

HOLD

Current Price

$26.00

Market Cap

55.6M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.52

Market Cap

57.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDRY
BOLD
Founded
2018
2018
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
55.6M
57.5M
IPO Year
2018
2024

Fundamental Metrics

Financial Performance
Metric
EDRY
BOLD
Price
$26.00
$2.52
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
82.9K
183.0K
Earning Date
06-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.30
N/A
Revenue Next Year
$10.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.00
$0.96
52 Week High
$28.00
$2.79

Technical Indicators

Market Signals
Indicator
EDRY
BOLD
Relative Strength Index (RSI) 63.51 65.12
Support Level $18.21 $2.35
Resistance Level $28.00 $2.64
Average True Range (ATR) 1.53 0.09
MACD 0.25 -0.03
Stochastic Oscillator 93.90 51.11

Price Performance

Historical Comparison
EDRY
BOLD

About EDRY EuroDry Ltd.

EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: